BridgeBio Pharma Q4 EPS $(0.96) Misses $(0.91) Estimate, Sales $1.75M Down From $1.87M YoY
Portfolio Pulse from Benzinga Newsdesk
BridgeBio Pharma (NASDAQ:BBIO) reported Q4 earnings with a loss of $(0.96) per share, missing the $(0.91) estimate, and sales of $1.75M, down 6.68% YoY from $1.87M.
February 22, 2024 | 12:51 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
BridgeBio Pharma reported a larger than expected quarterly loss and a decrease in sales compared to last year.
Missing the earnings estimate and reporting a year-over-year decrease in sales are negative indicators that could lead to a short-term decrease in stock price. Investors typically react unfavorably to earnings misses and declining sales figures, which can put downward pressure on the stock.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100